<DOC>
	<DOCNO>NCT00009048</DOCNO>
	<brief_summary>This study evaluate effect experimental drug call EMD 128130 Parkinson 's disease symptom dyskinesias ( involuntary movement ) develop result long-term treatment levodopa . EMD 128130 inhibits function serotonin , chemical messenger think regulate dopamine release , thus affect Parkinson 's disease symptom . Patients relatively advance Parkinson 's disease 30 80 year age may eligible 3-phase study . - Phase 1 - Baseline Evaluation Participants medical history , physical examination , detailed neurologic evaluation , routine blood test , urinalysis electrocardiogram . A chest X-ray MRI CT scan brain do need . In addition , ACTH stimulation test do end study . For test , hormone call ACTH inject vein . A small amount blood drawn injection 30 60 minute afterwards measure level another hormone call cortisol . After test complete , patient , possible , stop take antiparkinsonian medication except levodopa ( Sinemet ) one month study begin throughout duration . - Phase 2 - Levodopa Apomorphine Dose Finding For 1 3 day , patient admit NIH Clinical center undergo levodopa apomorphine ( dopamine agonist ) `` dose-finding '' procedure . For procedure , patient stop take Sinemet instead levodopa , subsequently apomorphine , infused vein . During infusion , drug dose increase slowly either 1 ) parkinsonian symptom improve , 2 ) unacceptable side effect occur , 3 ) maximum study dose reach . Symptoms monitor frequently find two infusion rate : 1 ) one less need relieve symptom , 2 ) one relieve symptom may produce dyskinesia . - Phase 3 - Active Study Patients begin treatment phase within 3 month dose-finding phase . After brief physical examination , routine blood test , evaluation parkinsonism symptom , patient begin take either EMD 128130 tablet capsule placebo ( look-alike pill active ingredient ) twice day , along Sinemet , 3 week . All participant receive placebo least 1 week study , four patient , select random , receive placebo entire 3 week . Levodopa apomorphine infusion repeat end week 1 , 2 3 Phase 3 . The procedure infusions dose-finding phase . Throughout study , parkinsonian symptom dyskinesia assess blood sample draw periodically measure drug level . Patients return follow-up evaluation 2 week end study .</brief_summary>
	<brief_title>EMD 128130 Treatment Parkinson 's Disease</brief_title>
	<detailed_description>The objective study evaluate acute effect selective agonist serotonin 5-HT1A receptor severity parkinsonian sign levodopa-associated motor response complication patient moderately advance Parkinson 's disease . In controlled proof-of-principle clinical trial , efficacy EMD 128130 assess use validate motor function scale . Safety monitor mean frequent clinical evaluation laboratory test .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Males female age 3080 . Females must either least one year postmenopausal , use adequate contraceptive method least one month prior participation study . Patients carry diagnosis idiopathic Parkinson 's disease base presence characteristic clinical history neurologic finding . Patients relatively advanced disease levodopaassociated motor response complication , include peakdose dyskinesia wearingoff fluctuation . Patients presence history medical condition reasonably expect subject patient unwarranted risk exclude . Patients clinically significant laboratory abnormality include liver enzyme elevation two time upper limit normal exclude . Patients unable treated levodopa/carbidopa alone single , relatively shortacting dopamine agonist exclude . Patients form parkinsonism idiopathic PD exclude . Patients unacceptable prior/concomitant medication exclude . No pregnant woman . Female male patient must practice effective mean birth control . Patients prior bilateral surgical intervention treatment parkinsonian symptom , i.e . deep brain stimulation , pallidotomy , fetal tissue transplantation exclude . Patients risk hypotension , cardiac arrhythmia , and/or myocardial ischemia secondary intravenous levodopa challenge eligible . Patients cognitive impairment ( MMSE less 25 ) eligible . Patients subnormal serum cortisol response acute ACTH stimulation exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Dyskinesias</keyword>
	<keyword>L-Dopa Infusion</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Motor Function</keyword>
	<keyword>Psychosis</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>